Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria
ArticleAbstract: Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation-3) found that antihypPalabras claves:Blood pressure, candesartan, Cardiovascular disease, Lipoprotein, Primary Prevention, statinAutores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Gao P., Hart R.G., Held C., Khunti K., Leiter L.A., Lewis B.S., Lonn E.M., Pais P., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Reid C.M., Sliwa K., Toff W.D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusFixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
ArticleAbstract: Background: In randomised controlled trials, fixed-dose combination treatments (or polypills) have bPalabras claves:Autores:Avezum A.J., Bangdiwala S.I., Bosch J.J., Castellano J.M., Dagenais G.R., Dans A.M., DIaz R., Fuster V., Gamra H., Gao P., Huffman M.D., Joseph P.G., Liu L., Lonn E.M., Malekzadeh R., Pais P., PATRICIO LOPEZ -JARAMILLO, Prabhakaran D., Rodgers A., Roshandel G., Sliwa K., Teo K.K., Xavier D., Yusuf S., Zhu J.Fuentes:googlescopusHealth-Related Quality of Life and Mortality in Heart Failure The Global Congestive Heart Failure Study of 23000 Patients From 40 Countries
ArticleAbstract: BACKGROUND: Poor health-related quality of life (HRQL) is common in heart failure (HF), but there arPalabras claves:health status, Heart Failure, Left, prognosis, quality of life, Ventricular functionAutores:Alhabib K.F., Balasubramanian K., Bayes-Genis A., Budaj A.J., Dans A.M., Dokainish H., Dzudie A., Ezekowitz J.A., Fox K.A.A., Fukakusa B., Grinvalds A., Johansson I., Joseph P.G., Kamath D., Karaye K.M., Lanas F.T., Lund L.H., Maggioni A.P., Makubi A., McCready T., McMurray J.J.V., PATRICIO LOPEZ -JARAMILLO, Probstfield J.L., Silva-Cardoso J., Sliwa K., Temizhan A., Teo K.K., Wittlinger T., Yusuf S.Fuentes:googlescopusLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopus